News Sentiment

XFOR sentiment intelligence

X4 Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 51 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 4.41 Week of 10 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

82/100 classification confidence.

Company focus 43

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

+6.8% over one week, +10.3% over four weeks, trend active, and below fair value.

Latest direct headline Neutral

X4 Pharmaceuticals (XFOR) Proxy filing Summary

Market Reaction

Price moving ahead of tone

65/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 82/100 classification
One-week reaction 6.8% Price confirming higher
Trend fit Trend active 10.3% over four weeks
Fair value -72.0% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 34
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 43
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 10
Market source 9
TradingView 6
Quartr 5
Investing.com Canada 3
Ad-hoc-news.de 3
GlobeNewswire 3
simplywall.st 3

Event Lens

What the news is about

Classified themes
Market update 31
Earnings 17
Analyst action 2
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 51
Quartr Direct company coverage

X4 Pharmaceuticals (XFOR) Proxy filing Summary

X4 Pharmaceuticals has released a proxy filing summary detailing the upcoming annual meeting on May 11, 2026. Stockholders will vote on director elections, auditor ratification, an equity plan amendment, and executive compensation. The Board recommends approving all proposals, an

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 14:41
Source
Quartr
Quartr Direct company coverage

X4 Pharmaceuticals (XFOR) Q4 2025 earnings summary

X4 Pharmaceuticals (XFOR) reported its Q4 2025 earnings, highlighting that enrollment for its 4WARD Phase 3 chronic neutropenia trial is on track for completion in Q3 2026 and expects final EU approval for mavorixafor for WHIM syndrome in Q2 2026. The company posted net product s

Tone
Positive 72/100
Event
Earnings
Published
13 Jul 2026 13:12
Source
Quartr
Quartr Direct company coverage

X4 Pharmaceuticals (XFOR) Corporate presentation Summary

X4 Pharmaceuticals is focused on developing mavorixafor for chronic neutropenia, with its Phase 3 4WARD study fully enrolling by Q3 2026. The company secured $240M, reduced its workforce by 50%, and expects its cash runway to last through 2028. Mavorixafor, already approved for W

Tone
Positive 76/100
Event
Guidance
Published
13 Jul 2026 00:41
Source
Quartr
Quartr Direct company coverage

X4 Pharmaceuticals (XFOR) Registration filing Summary

X4 Pharmaceuticals (XFOR) has filed a registration summary, detailing its focus on developing therapeutics for rare hematology diseases, primarily with its main asset, mavorixafor. The company provided financial metrics as of March 31, 2026, including outstanding shares and per-s

Tone
Positive 59/100
Event
Market update
Published
13 Jul 2026 00:41
Source
Quartr
Quartr Direct company coverage

X4 Pharmaceuticals (XFOR) Q1 2026 earnings summary

X4 Pharmaceuticals reported a Q1 2026 net loss of $20.2 million, a significant drop from Q1 2025's net income, primarily due to lower license revenue despite increased product revenue from XOLREMDI. The company is focused on commercializing XOLREMDI, recently approved in the EU,

Tone
Neutral 50/100
Event
Earnings
Published
13 Jul 2026 00:41
Source
Quartr
Investing.com Canada Direct company coverage

Wells Fargo initiates X4 Pharmaceuticals stock coverage with overweight rating by Investing.com

Wells Fargo has initiated coverage on X4 Pharmaceuticals (NASDAQ:XFOR) with an overweight rating and an $11.00 price target, citing the potential of its drug candidate mavorixafor for chronic neutropenia. A Phase 3 trial readout is anticipated in the second half of 2027, with the

Tone
Positive 72/100
Event
Analyst action
Published
10 Jul 2026 10:39
Source
Investing.com Canada
Ad-hoc-news.de Direct company coverage

X4 Pharmaceuticals stock focuses on rare disease pipeline after Nasdaq listing

X4 Pharmaceuticals, trading on Nasdaq as XFOR, is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for rare primary immunodeficiency and related disorders. Its strategy centers on niche medical needs and orphan drug designation, providing

Tone
Positive 65/100
Event
Market update
Published
09 Jul 2026 15:07
Source
Ad-hoc-news.de
Stock Titan Direct company coverage

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

X4 Pharmaceuticals (Nasdaq: XFOR) has granted 750,000 stock options to new employees as inducement awards under its 2019 Inducement Equity Incentive Plan, effective July 6, 2026. The options have an exercise price of $4.03 per share, matching the closing price on the grant date,

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 20:10
Source
Stock Titan
TradingView Direct company coverage

Price to earnings forward of X4 Pharmaceuticals, Inc. – NASDAQ:XFOR

This article provides the "Price to earnings forward" metric for X4 Pharmaceuticals, Inc. (NASDAQ: XFOR). The information, sourced from TradingView and FactSet, is presented without specific numerical values but indicates the availability of financial data for the company. The co

Tone
Neutral 50/100
Event
Earnings
Published
06 Jul 2026 12:40
Source
TradingView
Intellectia AI Direct company coverage

XFOR Stock News Today | Earnings, Events & Price Alerts

This article provides recent news and event updates for X4 Pharmaceuticals (XFOR). Key highlights include recent grants of inducement awards to new employees, the appointment of Kelly Gold to the Board of Directors, and the completion of EU approval for XOLREMDI®, along with posi

Tone
Positive 70/100
Event
Earnings
Published
06 Jul 2026 11:11
Source
Intellectia AI
TradingView Direct company coverage

Price to sales forward of X4 Pharmaceuticals, Inc. – NASDAQ:XFOR

This article focuses on the "Price to sales forward" financial metric for X4 Pharmaceuticals, Inc. (NASDAQ: XFOR). It appears to be a stub or a section within a larger financial data platform, providing a snapshot of this specific valuation ratio for the company without further d

Tone
Neutral 50/100
Event
Market update
Published
05 Jul 2026 02:09
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of X4 Pharmaceuticals, Inc. – NASDAQ:XFOR

This article focuses on the enterprise value to EBITDA forward for X4 Pharmaceuticals, Inc. (NASDAQ: XFOR). The content, likely financial data, is presented through TradingView, a financial platform. It indicates that the market is closed and no trades have occurred for the speci

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 11:10
Source
TradingView
Stock Titan Direct company coverage

Kelly Gold joins X4 Pharmaceuticals (Nasdaq: XFOR) board and Audit Committee

X4 Pharmaceuticals (Nasdaq: XFOR) has appointed Kelly Gold as a Class II independent director to its Board, effective July 1, 2026. This appointment expands the board from five to six members, and Gold will also serve on the Audit Committee. Gold brings extensive financial leader

Tone
Positive 64/100
Event
Market update
Published
01 Jul 2026 20:40
Source
Stock Titan
Stock Titan Direct company coverage

X4 Pharmaceuticals (XFOR) director Gold Kelly files initial Form 3 ownership

X4 Pharmaceuticals director Gold Kelly has filed an initial Form 3, indicating her beneficial ownership status as a director. This filing serves as a baseline disclosure and does not report any insider stock transactions or derivative securities. The Form 3 details Kelly's positi

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 20:40
Source
Stock Titan
Investing.com Canada Direct company coverage

Form 4 X4 Pharmaceuticals Inc For: 1 July By Investing.com

This article from Investing.com reports the filing of Form 4 for X4 Pharmaceuticals Inc., dated July 1st. Form 4 is a document that must be filed with the SEC whenever a company insider (such as an officer, director, or 10%+ shareholder) trades the company's stock. The article pr

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 20:40
Source
Investing.com Canada
Stock Titan Direct company coverage

Director Kelly Gold granted 110,000 X4 Pharmaceuticals (XFOR) stock options at $4.085

X4 Pharmaceuticals director Kelly Gold was granted 110,000 stock options with an exercise price of $4.085 per share, expiring on July 1, 2036. These options vest fully on the one-year anniversary of the grant date, provided Gold continues to provide services to the company. Follo

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 20:40
Source
Stock Titan
Stock Titan Direct company coverage

X4 Pharmaceuticals (XFOR) CFO sells 8,543 shares to cover RSU tax

X4 Pharmaceuticals' CFO, David Kirske, sold 8,543 shares of common stock at a weighted average price of $4.2641 per share. This sale was conducted to satisfy a personal income tax obligation arising from the settlement of a restricted stock unit (RSU) award. Following the transac

Tone
Negative 41/100
Event
Market update
Published
01 Jul 2026 20:40
Source
Stock Titan
Investing.com Canada Direct company coverage

X4 Pharmaceuticals appoints Kelly Gold to board of directors By Investing.com

X4 Pharmaceuticals has appointed Kelly Gold to its board of directors, effective immediately. Gold, who is currently the CFO of CAMP4 Therapeutics, will also serve on the audit committee. Her appointment comes as X4 Pharmaceuticals continues to advance its therapies for rare hema

Tone
Positive 61/100
Event
Market update
Published
01 Jul 2026 11:39
Source
Investing.com Canada
Stock Titan Direct company coverage

X4 Pharmaceuticals adds CAMP4 CFO Kelly Gold to its board

X4 Pharmaceuticals (Nasdaq: XFOR) has appointed Kelly Gold, the current Chief Financial Officer at CAMP4 Therapeutics, to its Board of Directors, effective July 1, 2026. Ms. Gold will serve as an independent director and a member of the Audit Committee, bringing significant finan

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 10:39
Source
Stock Titan
www.marketscreener.com Direct company coverage

X4 Pharmaceuticals, Inc.(NasdaqCM: XFOR) added to Russell 2000 Index

X4 Pharmaceuticals, Inc. (NasdaqCM: XFOR), a biopharmaceutical company specializing in rare immune-related diseases, has been included in the Russell 2000 Index. The article also notes its addition to other Russell indexes, including the Russell 2000 Value Benchmark, Russell Micr

Tone
Positive 72/100
Event
Market update
Published
29 Jun 2026 18:51
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

X4 Pharmaceuticals, Inc.(NasdaqCM: XFOR) added to Russell Microcap Index

X4 Pharmaceuticals, Inc. (NasdaqCM: XFOR) has been added to the Russell Microcap Index. This inclusion follows an earlier announcement that the company was also added to the Russell 3000E Index. X4 Pharmaceuticals is a commercial-stage biopharmaceutical company focused on develop

Tone
Positive 74/100
Event
Market update
Published
29 Jun 2026 05:39
Source
www.marketscreener.com
Ad-hoc-news.de Direct company coverage

X4 Pharmaceuticals updates investor plans, shares remain thinly traded on Nasdaq

X4 Pharmaceuticals (XFOR) is updating investors on its clinical pipeline and funding strategy, particularly for its lead candidate mavorixafor targeting rare diseases linked to CXCR4 pathway dysfunction. Despite outlining key milestones and potential strategic options, the compan

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 13:09
Source
Ad-hoc-news.de
TradingView Direct company coverage

48Q0 Forecast — Price Target — Prediction for 2027

This article provides a forecast and price target for X4 Pharmaceuticals, Inc. (48Q0) on the Frankfurt Stock Exchange, based on analyst opinions. It details historical price data, earnings reports, revenue figures, net income, and other financial metrics for the company. The repo

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 07:09
Source
TradingView
TradingView Direct company coverage

X4 Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:XFOR)

This article provides financial actuals and estimates for X4 Pharmaceuticals, Inc. (NASDAQ:XFOR), including its current stock price, market capitalization, earnings, and revenue. It also covers analyst forecasts, historical price movements, volatility, and details on upcoming ear

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 06:10
Source
TradingView
Ad-hoc-news.de Direct company coverage

X4 Pharmaceuticals, Thursday trading bias in shares

X4 Pharmaceuticals (XFOR) is listed on NASDAQ, and its shares traded based on a broad market tone on Thursday, June 25, 2026. The stock's performance is contextualized by larger U.S. growth names and the day's risk appetite, with Micron dominating early market coverage. The compa

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 11:41
Source
Ad-hoc-news.de
TradingKey Direct company coverage

X4 Pharmaceuticals Inc (XFOR) Institutional Confidence

X4 Pharmaceuticals Inc (XFOR) currently holds an institutional shareholding score of 3.00, placing it 94th out of 157 in the Pharmaceuticals industry. The institutional shareholding proportion is 9.67%, marking an 89.43% decrease quarter-over-quarter. Bill Nygren from OAKMX is no

Tone
Neutral 50/100
Event
Market update
Published
19 Jun 2026 03:10
Source
TradingKey